CDLX stock analysis


Aime
Cardlytics, Inc. (CDLX) Stock Analysis:
- Recent Performance:
- Stock Price Movement: As of September 20, 2024, CDLX closed at $2.96, a significant drop from its pre-market trading low of $2.22 on August 8, 20241.
- Technical Indicators:
- The Moving Average Convergence Divergence (MACD) is at 0.33, indicating a potential upward momentum2.
- The Relative Strength Index (RSI) is at 48.29, suggesting that the stock is neither overbought nor oversold2.
- The KDJ indicator is at 85.85, which could indicate an overbought condition2.
- The stock is currently trading below its Bollinger Band lower band of $3.192.
- Analyst Ratings and Price Targets:
- The consensus rating among analysts is a "Neutral" with an average price target of $5.25, indicating a potential upside from the current price3.
- Analysts have lowered their price targets for the stock, reflecting a negative sentiment4.
- Financial Performance:
- CDLX reported a 9% year-over-year decrease in revenue to $69.6 million and a 3% decline in adjusted contribution to $36.4 million in Q2 202451.
- The company's stock dropped by 57.10% on August 8, 2024, following the disclosure of financial results and management changes51.
- Legal and Regulatory Issues:
- CDLX is under investigation for potential securities fraud and other unlawful business practices51.
- There are class action lawsuits against the company concerning possible violations of federal securities laws51.
- Management and Operational Issues:
- The company experienced a change in CEO and board members following the disclosure of financial results5.
- There are concerns about the company's ability to execute on its growth initiatives and technological strides54.
Conclusion: CDLX faces significant challenges, including a decline in revenue, legal investigations, and operational concerns. While the stock is currently undervalued, the high level of risk associated with the company's legal and financial uncertainties suggests that investors should proceed with caution.
Source:
more
less
Continue this conversation 

Explore
Screener
Analysis
Learn
News